结论：白三烯受体拮抗剂在治疗哮喘患儿中起抗炎作用。
Conclusion: Leukotrienes receptor antagonist had anti-inflammatory effect in the treatment of asthma.
目的研究白三烯受体拮抗剂-扎鲁司特对运动性哮喘的治疗作用。
Objective Zafirlukast, leukotriene receptor antagonist, is introduced in this study to investigate its effect on exercise induced bronchospasm.
孟鲁司特，选择性白三烯受体1拮抗物，能减少雨蛙肽诱导的胰腺损害。
Montelukast, a Selective Cysteinyl Leukotriene Receptor 1 Antagonist, Reduces Cerulein-Induced Pancreatic Injury in Rats.
结论短期应用白三烯受体拮抗剂可改善哮喘患者乙酰甲胆碱支气管激发试验剂量-反应曲线参数。
Conclusion Short term use of Zafirlucast in asthmatic patients could improve the parameters of dose response curve obtained after the methacholine challenge test.
初步药理结果表明化合物（51），（68），（89）和（95）对白三烯D_4受体有较好的拮抗作用。
Pharmacological tests showed that compounds (51), (68), ( 89) and (95) have strong antagonism on the D4 recepter of Leukotriene (LTD4).
目的探讨了血清可溶性白细胞介素-2受体（SIL-2R）和半胱氨酰白三烯（LTS）水平在支气管肺炎患儿治疗前后的变化及意义。
Objective To investigate the significance of changes of serum SIL-2R and cysteine LTS levels after treatment in pediatric patients with bronchopneumonia.
目的探讨白三烯（LT）B4能否不依赖细胞核因子资B受体激活剂配体（RANKL）直接促进人破骨细胞的分化和激活。
Objective To determine whether leukotriene B4 (LTB4) could directly stimulate human osteoclast differentiation and activation independent of RANKL (ODF).
目的探讨白三烯（LT）B4能否不依赖细胞核因子资B受体激活剂配体（RANKL）直接促进人破骨细胞的分化和激活。
Objective To determine whether leukotriene B4 (LTB4) could directly stimulate human osteoclast differentiation and activation independent of RANKL (ODF).
应用推荐